Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study)

Abstract

Lung adenosquamous carcinoma (ASC) is a rare histological subtype of non-small cell lung cancer (NSCLC), and prospective data regarding the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in this patient population remain scarce. This prospective, multicenter, single-arm phase II trial (NCT04354961) evaluated the safety and efficacy of aumolertinib as first-line treatment for treatment-naïve patients with stage IV EGFR-mutant ASC. Eligible patients received aumolertinib 110 mg orally once daily, with progression-free survival (PFS) as the primary endpoint and objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety as secondary endpoints. The study was terminated early due to slow accrual, with 12 patients enrolled (median age: 66 years; 58.3% male; 58.3% with EGFR exon 19 deletion). After a median follow-up of 29.0 months, the median PFS and OS were 11.1 months (95% CI, 4.27–NA) and 16.7 months (95% CI, 11.3–NA), respectively. Confirmed ORR and DCR were 58.3% and 83.3%. Treatment-related adverse events (TRAEs) occurred in 75% of patients, with 33.3% experiencing grade 3–4 TRAEs; no treatment-related deaths were observed. Aumolertinib exhibits clinical activity with a manageable safety profile in EGFR-mutant ASC patients. However, its reduced efficacy compared with EGFR-mutant adenocarcinoma highlights the need for histology-specific therapeutic strategies.

Keywords

aumolertinib / EGFR-mutant / first-line treatment / lung adenosquamous carcinoma

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] A. C. Borczuk, “Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma,” Archives of Pathology & Laboratory Medicine 142, no. 8 (2018): 914–921.

[3] C. Li and H. Lu, “Adenosquamous Carcinoma of the Lung,” OncoTargets and Therapy 11 (2018): 4829–4835.

[4] G. Lin, C. Li, P. S. Li, et al., “Genomic Origin and EGFR-TKI Treatments of Pulmonary Adenosquamous Carcinoma,” Annals of Oncology 31, no. 4 (2020): 517–524.

[5] C. Zappa and S. A. Mousa, “Non-Small Cell Lung Cancer: Current Treatment and Future Advances,” Translational Lung Cancer Research 5, no. 3 (2016): 288–300.

[6] E. Roci, B. Cakani, G. Brace, et al., “Platinum-Based Chemotherapy in Recurrent High-Grade Glioma Patients: Retrospective Study,” Medical Archives 68, no. 2 (2014): 140–143.

[7] B. L. Parsons, “Multiclonal Tumor Origin: Evidence and Implications,” Mutation Research – Reviews in Mutation Research 777 (2018): 1–18.

[8] W. G. Hammond, H. Tesluk, and J. R. Benfield, “Histogenesis of Adenosquamous Bronchogenic Carcinoma,” Cancer Letters 96, no. 2 (1995): 163–168.

[9] Y. Shi, J. S. K. Au, S. Thongprasert, et al., “A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients With Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER),” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 9, no. 2 (2014): 154–162.

[10] E. Santoni-Rugiu, L. C. Melchior, E. M. Urbanska, et al., “Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities With Acquired Resistance,” Cancers 11, no. 7 (2019): 923.

[11] S. Lu, Q. Wang, G. Zhang, et al., “Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial,” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 17, no. 3 (2022): 411–422.

[12] T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi, “Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer: Biological and Clinical Implications,” Cancer Research 64, no. 24 (2004): 8919–8923.

[13] G. J. Riely, D. E. Wood, D. S. Ettinger, et al., “Non–Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 22, no. 4 (2024): 249–274.

[14] S. Lu, X. Dong, H. Jian, et al., “AENEAS: A Randomized Phase III Trial of Aumolertinib versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations,” Journal of Clinical Oncology 40, no. 27 (2022): 3162–3171.

[15] H. P. Yu, M. S. Wei, Y. Y. Cui, et al., "EGFR inhibitors, Their Preparation and Their Use Thereof", TW201613875A, Accessed November 29, 2024, https://patents.google.com/patent/TW201613875A/en.

[16] M. A. Socinski, G. M. Manikhas, D. L. Stroyakovsky, et al., “A Dose Finding Study of Weekly and Every-3-Week Nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 5, no. 6 (2010): 852–861.

[17] "Clovis Oncology Announces Regulatory Update for Rociletinib NDA filing", Business Wire, May 27, 2025, https://www.businesswire.com/newsroom.

[18] X. Xu, L. Mao, W. Xu, et al., “AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients,” Molecular Cancer Therapeutics 15, no. 11 (2016): 2586–2597.

[19] P. A. Jänne, J. C. H. Yang, D. W. Kim, et al., “AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer,” New England Journal of Medicine 372, no. 18 (2015): 1689–1699.

[20] J. C. Soria, Y. Ohe, J. Vansteenkiste, et al., “Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer,” New England Journal of Medicine 378, no. 2 (2018): 113–125.

[21] I. Sullivan and D. Planchard, “Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer Beyond First Line,” Frontiers in Medicine 3 (2017): 76.

[22] H. Li, W. Zhao, C. Chang, et al., “Efficacy and Patient-Reported Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Aumolertinib as First-Line Therapy: A Real-World Study,” Frontiers in Pharmacology 15 (2024): 1444707.

[23] C. S. Tan, N. B. Kumarakulasinghe, Y. Q. Huang, et al., “Third Generation EGFR TKIs: Current Data and Future Directions,” Molecular Cancer 17 (2018): 29.

[24] P. Liu, M. Ji, Y. Kong, et al., “Comparison of Survival Outcomes Between Squamous Cell Carcinoma and Adenocarcinoma/Adenosquamous Carcinoma of the Cervix After Radical Radiotherapy and Chemotherapy,” BMC Cancer 22, no. 1 (2022): 326.

[25] Z. Song, B. Lin, L. Shao, and Y. Zhang, “Therapeutic Efficacy of Gefitinib and Erlotinib in Patients With Advanced Lung Adenosquamous Carcinoma,” Journal of the Chinese Medical Association 76, no. 9 (2013): 481–485.

[26] S. Batson, S. A. Mitchell, R. Windisch, E. Damonte, V. C. Munk, and N. Reguart, “Tyrosine Kinase Inhibitor Combination Therapy in First-Line Treatment of Non-Small-Cell Lung Cancer: Systematic Review and Network Meta-Analysis,” OncoTargets and Therapy 10 (2017): 2473–2482.

[27] F. Pan, S. Cui, W. Wang, A. Gu, and L. Jiang, “Survival Analysis for Lung Adenosquamous Carcinoma Patients With Brain Metastasis,” Journal of Cancer 9, no. 20 (2018): 3707–3712.

[28] D. Westover, J. Zugazagoitia, B. C. Cho, C. M. Lovly, and L. Paz-Ares, “Mechanisms of Acquired Resistance to First- and Second-Generation EGFR Tyrosine Kinase Inhibitors,” Annals of Oncology 29 (2018): i10–i19.

[29] U. Testa, G. Castelli, and E. Pelosi, “Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells,” Cancers 10, no. 8 (2018): 248.

[30] J. Xu, Y. Zhang, B. Jin, et al., “Efficacy of EGFR Tyrosine Kinase Inhibitors for Non-Adenocarcinoma Lung Cancer Patients Harboring EGFR-Sensitizing Mutations in China,” Journal of Cancer Research and Clinical Oncology 142, no. 6 (2016): 1325–1330.

[31] L. V. Sequist, B. A. Waltman, D. Dias-Santagata, et al., “Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors,” Science Translational Medicine 3, no. 75 (2011): 75ra26.

[32] S. Shinohara, Y. Ichiki, Y. Fukuichi, et al., “Squamous Cell Carcinoma Transformation From Adenocarcinoma as an Acquired Resistance After the EGFR TKI Therapy in (EGFR-Mutated) Non-Small Cell Lung Cancer,” Journal of Thoracic Disease 10, no. 7 (2018): E526–E531.

[33] F. R. Hirsch, K. Suda, J. Wiens, and P. A. Bunn, “New and Emerging Targeted Treatments in Advanced Non-Small-Cell Lung Cancer,” Lancet 388, no. 10048 (2016): 1012–1024.

[34] H. Watanabe, T. Tamura, K. Kagohashi, M. Kawaguchi, K. Kurishima, and H. Satoh, “Successful Pemetrexed-Containing Chemotherapy for Epidermal Growth Factor Receptor Mutation-Positive Adenosquamous Cell Carcinoma of the Lung: A Case Report,” Molecular and Clinical Oncology 4, no. 4 (2016): 628–630.

[35] J. Wei, J. Xiang, Y. Hao, et al., “Clinical Outcomes of Immune Checkpoint Inhibitor Therapy for Advanced Lung Adenosquamous Carcinoma,” Journal of Thoracic Disease 15, no. 2 (2023): 260–269.

[36] L. Leung, T. S. K. Mok, and H. Loong, “Combining Chemotherapy With Epidermal Growth Factor Receptor Inhibition in Advanced Non-Small Cell Lung Cancer,” Therapeutic Advances in Medical Oncology 4, no. 4 (2012): 173–181.

[37] Y. Cheng, Y. He, W. Li, et al., “Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study,” Targeted Oncology 16, no. 2 (2021): 165–176.

[38] S. Lu, J. Hu, J. Chen, et al., “Abstract CT053: Aumolertinib With or Without Chemotherapy as First Line Treatment in Locally Advanced or Metastatic NSCLC With Sensitizing EGFR Mutations (AENEAS2),” Cancer Research 85, no. 8_Supplement_2 (2025): CT053.

[39] J. He, C. Su, W. Liang, et al., “Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial,” Lancet Respiratory Medicine 9, no. 9 (2021): 1021–1029.

[40] J. C. Soria, Y. L. Wu, K. Nakagawa, et al., “Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer After Progression on First-Line Gefitinib (IMPRESS): A Phase 3 Randomised Trial,” Lancet Oncology 16, no. 8 (2015): 990–998.

[41] D. Planchard, P. A. Jänne, Y. Cheng, et al., “Osimertinib With or Without Chemotherapy in EGFR-Mutated Advanced NSCLC,” New England Journal of Medicine 389, no. 21 (2023): 1935–1948.

[42] M. Wen, J. Xia, Y. Sun, et al., “Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation,” Biologics: Targets and Therapy 12 (2018): 183–190.

[43] L. Bazhenova, N. Ismaila, F. Abu Rous, et al., “Therapy for Stage IV Non–Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2024.2,” Journal of Clinical Oncology 42, no. 36 (2024): e72–e86.

[44] P. Abdayem and D. Planchard, “FLAURA Strikes Again: Efficacy of Osimertinib Is Independent of PD-L1 Expression,” Translational Lung Cancer Research 9, no. 5 (2020): 2165–2172.

[45] V. Velcheti, J. Moore, and C. T. Solem, “Treatments and Outcomes After Platinum-Based Chemotherapy and Anti–PD-(L)1 in NSCLC,” JAMA Network Open 8, no. 6 (2025): e2514527.

[46] P. Therasse, S. G. Arbuck, E. A. Eisenhauer, et al., “New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” JNCI: Journal of the National Cancer Institute 92, no. 3 (2000): 205–216.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.